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GUEST EDITORIAL
Are cancer cells acidic?
J.R. Griffiths
CRC Biomedical Magnetic Resonance Research Group, St George's Hospital Medical School, Cranmer Terrace,
London SW17 ORE, UK.
For more than half a century it has been generally believed
that cancer cells are more acidic than normal cells. This
dogma arose from the studies of Warburg and co-workers
(Warburg, 1930) who showed that tumour cells preferentially
convert glucose and other substrates to lactic acid, even
under aerobic conditions. Since lactic acid has a pK of 3.7 it
seemed obvious that the intracellular fluid would become
acidic. Studies on cultured tumour cells or spheroids often
showed low intracellular pH (pHi) values, but this could have
been due to their highly artificial situation. What would be
the pHi of cells in a solid tumour in a patient?
The development of pH electrodes small enough to be
inserted into living tissues led to the apparent confirmation of
the prevailing wisdom. Numerous studies (reviewed by Wike-
Hooley et al., 1984 and Vaupel et al., 1989; see also Figure
lb) showed significantly more acidic pH (pHpoT) in tumours
than that in normal tissues. Microelectrodes that can be used
on solid tumours in vivo are usually quite large in com-
parison to a tumour cell (see Wike-Hooley et al., 1984, Table
II), and they mainly measure the pH of the extracellular fluid
(pHe) rather than pHi (Vaupel et al., 1989). For most pur-
poses, the parameter of interest is pH1, the pH of the water in
the cancer cell itself, but it was generally expected (and then
tacitly assumed) that pHi would also be acidic.
This supposed cellular acidity in tumours became part of
the mental wallpaper of oncologists and cancer researchers,
even though there was, for many years, no practical way to
measure pHi of intact human tumours. It had clinical conse-
quences, too, since anticancer treatments were often designed
to take advantage of a low pH, (for a review, see Wike-
Hooley et al., 1984). It was argued, for instance, that
anticancer drugs would be more effective if they contained
ionising groups that would cause them to be trapped in
acidic environments (Wike-Hooley et al., 1984), or that
radioresistant hypoxic cells would have a particularly low
pHi and might therefore be especially sensitive to treatments
such as hyperthermia which are known to act preferentially
on isolated cells in acidic media (Freeman et al., 1981). There
were also numerous attempts to lower pHi still further by
administration of glucose, and thereby enhance the action of
various pH-sensitive therapies (Ross, 1961, reviewed by
Wike-Hooley et al., 1984). In general, these ideas have had
little clinical success, but they are still the subject of active
research (see, for instance, Tannock & Rotin, 1989).
Within the last 10 years a non-invasive intracellular pH
meter - the Nuclear Magnetic Resonance Spectrometer - has
become widely available; it can be used on living tumours in
situ, both in experimental animals and in man. The results
obtained with these instruments have been surprising. Instead
of having the expected acidic pHi, the cells of intact tumours
turned out to be neutral, or a little alkaline, both in experi-
mental animals (Griffiths et al., 1981; Iles et al., 1982) and
man (Griffiths et al., 1983). Indeed, several studies by 31P
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Magnetic Resonance Spectroscopy (MRS) have shown that
human tumours were slightly more alkaline than the normal
tissues from which they arose (Oberhaensli et al., 1986,
Vaupel et al., 1989).
The results of a number of Magnetic Resonance Spectros-
copy examinations of pHi in normal human tissues and in
human tumours have been reviewed by Vaupel et al. (1989)
and compared with similar data from microelectrode studies.
They bear out the original pHMRS findings that most
tumours, like normal tissues, are near neutrality, or slightly
alkaline. In contrast, pHpOT, measured by microelectrodes, is
often more acidic in tumours than in normal tissues. Figure
la and b shows this difference graphically. Overall, the
pHMRS results for tumours and for normal tissues all lie in
the range pH 6.9-7.4, while the pHpOT values for normal
tissues lie in the range pH 7.2-7.6 Microelectrode studies of
tumours, on the other hand, have given a much wider range
ofpHpOT values, pH 5.6-7.6, with mean values mainly on the
acidic side of neutrality. There is a remarkable similarity
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Figure 1 Ranges ofpH values measured in solid human tumours
and normal human tissues by a, 3"P-MRS (pHMRS) or b, micro-
electrodes (pHpm). Modified, with additional data (Arnold et al.,
1990; Koutcher et al., 1990; Ng et al., 1989; Redmond et al.,
1989; Segebarth et al., 1989; Vogl et al., 1989), from Vaupel
et al. (1989).
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between the pH measurements made by the, two techniques in
normal tissues. Indeed, if there is a systematic difference
between pHMRs and pHpoT in normal tissues it is the latter
value that tends to be more alkaline, as can be seen in Figure
lb. It is only in tumours that the two techniques give such
divergent results.
The pHMRS data in Figure la are impressively consistent,
particularly since they are taken from 21 papers on human
tumours and 20 on normal human tissues. In any event,
unless there is a systematic error associated with the deter-
mination of pHi by 31P MRS, it seems clear that human
tumour cells are not, in fact, usually acidic. Could there be
such a systematic error? There is no space here to discuss all
the technical points concerning the validity of the MRS
method for measuring pH, and many of them are not ger-
mane to the question we are addressing. A detailed con-
sideration of the differences between the pHpoT and pHMRS
data makes clear that a very specific error would be required.
If pHi of tumour cells really is acidic (as suggested by the
pHpOT data) there would have to be an artifact that causes
pHMRS of such cells to be artificially high without affecting
pHMRS of normal cells. Furthermore, the pHpOT results are
not uniformly shifted: some of them are more acidic than the
pHMRs range whereas others overlap it. Our hypothetical
artefact would have to cause the pH of the most acidic cells
to be falsely estimated by MRS as neutral or alkaline, but
have no effect on the apparent pH of the cells that were
found to be neutral or alkaline by microelectrode measure-
ments. None of the possible artifacts in pHMRS measurement
is likely to give rise to an error of this kind.
Briefly, the MRS method for measuring pHi is based on
determining the resonant frequencies of Pi and a reference
compound, usually phosphocreatine or sometimes a-ATP; the
Pi peak shifts with pH whereas the reference peak does not.
The difference between these two (normalised) frequencies is
then compared with a standard titration curve, determined
under conditions intended to model those in the cell (Moon
& Richards, 1973; Prichard et al., 1983). Absolute pHi can be
determined by MRS with a precision of 0.06pH (Smith et
al., 1989); smaller relative changes are also reproducibly
detectable. Errors can arise from partial volume effects (when
some of the phosphocreatine signal, for instance, arises from
adjacent muscle rather than the tumour itself (see Smith et
al., 1989; Ng & Vijayakumar, 1989) but there seems to be no
reason to expect them to cause a systematic overestimate of
pHi in tumours and not in normal tissues. Another potential
source of error could arise if there were abnormally high
concentrations of Pi in the extracellular fluid of tumours, or
in necrotic regions. Bhujwalla (1988) has demonstrated that
tumour extracellular Pi concentration is not, in fact, abnor-
mally high, and that the Pi concentration in the necrotic
volumes of tumours is no higher than that in other extracel-
lular fluids (approximately 2mM). Stubbs and co-workers
have recently extended and confirmed these studies (Stubbs et
al., submitted for publication). Lastly, the ionic content of
the medium in which the standard titration is performed
must match that of the cell (Roberts & Jardetsky, 1981).
Conceivably, tumour cells might have abnormal ionic con-
tents.
Evidence in favour of using 31P-MRS studies of the Pi
chemical shift to measure pHi of solid tumours comes from
experiments in which probe molecules with suitable ionisa-
tion properties are inserted into the cytosol and their chem-
ical shift is measured. The classic experiment of this type was
performed by Gillies et al. (1982) who superfused isolated
Ehrlich Ascites cells with 2-deoxyglucose, which was phos-
phorylated in the cytosol to 2-deoxyglucose-6-phosphate
(DOG-6-P), a pH probe. The values for pHi from DOG-6-P
were essentially identical to those obtained using Pi as the
probe. This method gave less clear-cut results when it was
applied to the Walker carcinosarcoma, in vivo (Griffiths et
al., 1981). The value of pHidetermined from the DOG-6-P
peak was much less than that determined from the Pi peak.
In later experiments (Rodrigues & Griffiths, unpublished) we
have found that the abnormally low pH reported by the
DOG-6-P probe was a transient phenomenon, lasting about
15-20 min. Perhaps the sugar is taken up into a membrane-
bounded compartment (e.g. an endosome) that becomes tran-
siently acidic. Overall, these results do not cast serious doubt
on the use of Pi as a probe for pHi.
Fluorinated compounds can also act as MRS probes for
pHi (Stevens et al., 1984). For instance, it is possible to
estimate pHi from the pH-sensitive chemical shift of fluoro-
nucleotide compounds formed intracellularly from 5-fluor-
ouracil. McSheehy et al. (1989) reported values in the range
of pH 6.9-7.3 from Walker carcinosarcomas in rats. All
these values are consistent with those determined from the Pi
peak by 31p MRS.
Another minimally invasive determination of pHi has been
developed in recent years: Positron Emission Tomography of
["C]DMO (Rottenberg et al., 1984, Vaupel et al., 1989). This
also gives generally more alkaline results in brain tumours
than in normal brain, tending to confirm the pHMRS data.
There is clearly a paradox here. The pHi of tumour cells
(as measured by MRS) is close to neutrality, as is that of
normal cells. The (predominately) extracellular pH measured
in tumours by microelectrodes, on the other hand, tends to
be acidic, sometimes substantially so. To resolve this paradox
we must bear in mind that lactic acid is largely dissociated in
vivo to H+ and lactate-. The cell has a number of mech-
anisms for exporting H+ ions, and a carrier-mediated system
for exporting lactic acid (but not lactate-). To maintain a
constant pHi in the face of continuous generation of acid,
normal cells continuously export H+ ions. The pHMRS results
in Figure 1 suggest that tumour cells are able to do the same
thing, even though they probably generate larger amounts of
H+ ions in the form of lactic acid. The acidity of the extra-
cellular fluid, measured as pHPOT in Figure Ib, could be
caused by efflux of H+ ions from the tumour cells. It is well
known that tumours are poorly vascularised, and this could
result in the tumour interstitial fluid failing to equilibrate
rapidly with that of the host; consequently tumour extracel-
lular pH (pHe) could remain below the normal host pH, of
pH 7.4.
It should not, in fact, be surprising that tumour cells
maintain their pHi near neutrality. Tumours may remain
alive for periods ofmonths or even years so it is obvious that
in the long run their cells must export H+ at the same rate as
they synthesise it - otherwise they would dissolve. Pre-
sumably they use the same H+ exporting systems as normal
cells, and, as in normal cells, the homeostatic mechanism is
set to give a near-neutral pHi. If the H+ exporting systems
are significantly overloaded the tumour cell's passive
buffering mechanisms will eventually be overcome and it will
die. Otherwise pHi will stay near neutrality. The simplest
explanation for the more alkaline pHi observed in some
tumours would be a more active cellular proton extrusion.
Another paradox concerns the tumour lactate- concentra-
tion. Measurements of the lactate ion content of solid
tumours in animals do indeed show that it is present at
abnormally high concentrations (Griffiths et al., 1987), yet
the intracellular H+ content is, as we have seen, normal.
However, this is also to be expected. Lactate ions are not
extruded from tumour cells only the protonated form, i.e.
lactic acid, crosses the cell membrane (Spencer & Lehninger,
1976). The rate at which lactic acid is lost is proportional to
the difference between the intracellular and extracellular pH
(Masuda et al., 1990); if pHe becomes more acid while pH,
remains the same, lactic acid extrusion will be reduced and
lactate- ions will accumulate intracellularly
The relationship between tumour intracellular and extracel-
lular pH is therefore opposite to the conventional wisdom.
Instead of tumour cells being acidic they are neutral, or
slightly alkaline. It is the pH of the extracellular fluid, as
determined by microelectrodes that is acidic. Thus, if one
designs a drug with a low pK, intending it to partition
preferentially into acidic tumour cells, it is more likely to
partition preferentially into the tumour extracellular fluid,
where it will probably be useless, unless it interacts with the
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All these results are concerned with unperturbed tumours.
In the short term, it is certainly possible to lower the pHi of
animal tumours by a number of manoeuvres as can be
demonstrated by MRS. Glucose administration can cause
acidification (Evelhoch et al., 1984) as can drugs such as
hydralazine, that accentuate anaerobic metabolism by lower-
ing tumour blood flow (Tozer et al., 1990). In another study
by combined 31P and 'H MRS it was possible to induce
acidification and lactate formation in the rat SG prolac-
tinoma by stimulating the secretion of prolactin (Maxwell et
al., 1988). When the buffering power of tumour homogenates
was allowed for, the fall in pHi was exactly equivalent to the
rise in H+.
Strategies aimed at lowering pHi in human tumours by
enhancing lactic acid synthesis may still be successful, there-
fore, but only in the short term. This, of course, could be
sufficient, if the acidification is coordinated with a treatment
modality (radiotherapy, hyperthermia, etc.) that also acts in
the short term. Our ability to measure tumour pHi non-
invasively and repeatedly by MRS could make such strategies
practicable, as the behaviour of the individual tumour could
be followed.
There is a more important general point. For the past half
century, one of the few things we thought we knew about
tumour metabolism was the opposite of the truth. Now that
the correct state ofaffairs is evident we may be able to target
the real abnormalities (enhanced H+ extrusion and lactate
retention) rather than the illusory acidic tumour cell.
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